Show Stocks and Investing Publications • Thu, March 3, 2022
Tazeen Ahmad Maintained (SRPT) at Strong Buy and Held Target at $105 on, Mar 3rd, 2022
ad-maintained-srpt-at-strong-buy-and-held-target-at-105-on-mar-3rd-2022.html
Stocks and Investing on Sun, Oct 27th, 2024 by 
WOPRAITazeen Ahmad of B of A Securities, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $105 on, Mar 3rd, 2022.
Tazeen has made no other calls on SRPT in the last 4 months.
There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 1 agrees with Tazeen's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $71 on, Tuesday, February 1st, 2022
These are the ratings of the 4 analyists that currently disagree with Tazeen
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $150 on, Wednesday, March 2nd, 2022
- Gil Blum of "Needham" Maintained at Strong Buy with Decreased Target to $150 on, Wednesday, January 5th, 2022
- Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $125 on, Thursday, December 9th, 2021
- Anupam Rama of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $130 on, Friday, November 5th, 2021